Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options. Histone deacetylase inhibitors (HDACi) are a new class of anticancer agent that have demonstrated activity in hematological malignancies. Here, we investigated the efficacy and safety of HDACi (vorinostat, panobinostat, romidepsin) and novel combination therapies using in vitro human MM cell lines and in vivo preclinical screening utilizing syngeneic transplanted Vk*MYC MM. HDACi were combined with ABT-737, which targets the intrinsic apoptosis pathway, recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL/MD5-1), that activates the extrinsic apoptosis pathway or the DNA methyl transferase inhibitor 5-azacytidine. We demonstrate that in vitro cell line-based studies provide some insight into drug activity and combination therapies that synergistically kill MM cells; however, they do not always predict in vivo preclinical efficacy or toxicity. Importantly, utilizing transplanted Vk*MYC MM, we report that panobinostat and 5-azacytidine synergize to prolong the survival of tumor-bearing mice. In contrast, combined HDACi/rhTRAIL-based strategies, while efficacious, demonstrated on-target dose-limiting toxicities that precluded prolonged treatment. Taken together, our studies provide evidence that the transplanted Vk*MYC model of MM is a useful screening tool for anti-MM drugs and should aid in the prioritization of novel drug testing in the clinic.
Subject Category: Cancer
Multiple myeloma (MM) is an incurable malignancy of plasma cells 1, 2 characterized by clonal dysproteinemia, immune deregulation and end-organ toxicities associated with lytic bone destruction, renal failure, anemia and hypercalcemia. 3, 4 Advances in the treatment of MM have been made recently; 5 however, many patients fail to respond or relapse after initial response, highlighting the requirement for novel agents and combination regimens. 6, 7 Histone deacetylase inhibitors (HDACi) have demonstrated activity in hematological malignancies, [8] [9] [10] although resistance and dose-limiting toxicities are restricting their use. 11, 12 Here, we evaluated the potential of augmenting antitumor activities of HDACi by their combination with agents targeting multiple apoptotic pathways or DNA methyltransferases. Preclinical evaluation of efficacy and associated toxicities of this approach were evaluated using the Vk*MYC model of MM.
Vorinostat (suborylanilide hydroxamic acid (SAHA)), an HDACi targeting multiple HDACs and romidepsin (depsipeptide), a class I-selective HDACi, are FDA approved for the treatment of cutaneous T-cell lymphoma. 13, 14 Panobinostat (LBH-589), a cinnamic hydroxamic acid targeting multiple HDACs, 15 is undergoing phase III trials in combination with agents including bortezomib and dexamethasone in relapsed and refractory MM. HDACi induce apoptosis mainly via the intrinsic pathway 9 through events including altered cell cycle progression and/or cellular differentiation. 9, 13, [15] [16] [17] Hyperacetylation of non-histone proteins, including p53 and Hsp-90, may also have important roles in mediating antitumor effects of HDACi. 18 We posit that combining HDACi with agents targeting the intrinsic or extrinsic (death receptor) apoptotic pathways, or DNA-methyltransferases, could enhance therapeutic effects of HDACi 17 while reducing toxicities.
The intrinsic apoptotic pathway is regulated by prosurvival (e.g. Bcl-2, Bcl-X L ) and proapoptotic (e.g. Bax, Bak) multidomain Bcl-2 proteins, and Bcl-2 homology domain 3 (BH3)-only members. 19, 20 ABT-737, a BH3-only mimetic that binds Bcl-2, Bcl-X L and Bcl-w, acts by increasing the amount of free BH3-only proteins. [21] [22] [23] [24] [25] [26] The death receptor pathway is stimulated by ligands from the tumor necrosis factor (TNF) family, including TNF-related apoptosis-inducing ligand (TRAIL), binding to death receptors DR-4 (TRAIL-R1) or DR-5 (TRAIL-R2)) on human cells, or DR-5 on murine cells. 27, 28 Indeed, we have demonstrated that combining vorinostat with an agonistic anti-TRAIL receptor (TRAILR) antibody is more effective than single-agent treatment of breast cancer cell lines, 29, 30 whereas ABT-737 resensitizes Bcl-2-and Bcl-X L -overexpressing lymphoma cells to vorinostat. 31, 32 Recent work has demonstrated the potential for DNA methyltransferase inhibitors (DNMTi) in MM. 6, 33 DNMTi reportedly induce apoptosis in MM cells through the downregulation of Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling and nuclear factor-kB 6 and/or re-expression of epigenetically silenced genes, including tumor suppressors. 34 Promising preclinical data suggests that HDACi and DNMTi may synergize to induce apoptosis and tumor regression in MM.
The Vk*MYC transgenic mouse 3, 35 represents the pathogenesis and clinical manifestations of human MM. It relies on the activation of MYC in plasma cells leading to histopathological and immunophenotypic features of human MM, including progression from monoclonal gammopathy of undetermined significance (MGUS) to end-organ destructive plasma cell expansion. 35 Chng et al. 36 demonstrated MYC activation for the progression of human MGUS to MM, highlighting biological relevance of the Vk*MYC model. Moreover, Chesi et al. 3, 35 rigorously validated the ability of this model to predict single-agent drug activity in MM with a positive predictive value for clinical activity of 67% and a negative predictive value for clinical inactivity of 86%. Vk*MYC tumor cells are transplantable into syngeneic mice allowing for therapeutic experiments in large cohorts. 35 Here, we investigated the potential of combining HDACi with ABT-737, recombinant human TNF-related apoptosisinducing ligand (rhTRAIL)/MD5-1 or 5-azacytidine (5-AZA) in MM. We compared the effects of combination regimens in vitro in human MM cell lines with efficacy in vivo utilizing Vk*MYC MM. We demonstrate divergent effects of combination therapies in vivo compared with in vitro and identify toxicity profiles that only manifest in syngeneic model systems. We propose testing of new agents using Vk*MYC MM to aid in more rapid development of active and safe drug combinations for the treatment of MM. To demonstrate the correlation between HDACi-mediated target inhibition and induction of apoptosis, pharmacodynamic analyses were performed using panobinostat as a reference HDACi using detection of histone-H3 acetylation as the readout. Figure 1b shows the dose-dependent acetylation of histone-H3 in each human cell line with panobinostat (0-50 nM; 24 h).
Results

Differential
MM cell apoptosis is enhanced by combining HDACi with ABT-737. We have previously demonstrated that overexpression of prosurvival Bcl-2 proteins can inhibit HDACi-induced apoptosis. 31, 32, [37] [38] [39] We therefore determined whether relative sensitivities of MM cell lines to panobinostat were associated with the expression of Bcl-2 family members. Western blot analysis detected significant Bcl-2 expression in JJN3, OPM-2 and RPMI-8226, with barely detectable levels in U266 (Figure 2a ). Bcl-X L was detected in RPMI-8226 and U266, with little detected in JJN3 and OPM-2 cells. Mcl-1 was detected at high levels in all lines tested (Figure 2a) , whereas Bcl-w and Bcl-A1 were undetectable (positive controls showed antibody specificity, data not shown). Assessment of microarray expression data sets (Oncomine) suggested that all cell lines expressed Bcl-2, Mcl-1 and low levels of Bcl-w, whereas the expression of Bcl-X L and A1 correlated with protein levels by western blot (Supplementary Figure 1) . Collectively, these data failed to demonstrate any direct correlation between HDACi sensitivity and expression of prosurvival Bcl-2 family proteins. Given that all four MM cell lines expressed high levels of Bcl-2 and/or Bcl-X L , we assessed their sensitivity to ABT-737. 23, 24 All four cell lines were sensitive to ABT-737, with the U266 line being slightly more resistant (Figure 2b ).
Combining HDACi with ABT-737 kills B-cell lymphomas more potently than either agent alone, 31 and we therefore wished to determine the effect of this combination treatment against MM cells. The level of apoptosis following treatment of human MM cells with panobinostat and ABT-737 was significantly greater than single-agent treatment with a combination index (CI) o0.9 demonstrating synergistic cell killing (Figure 2c and Supplementary Figures 2A-D) . These studies indicate that combining HDACi with ABT-737 may be a potent method of killing MM cells.
Sensitivity of MM cells to the combination of HDACi and rhTRAIL. Previous studies have demonstrated that HDACi activate the extrinsic apoptosis pathway through the upregulation of death receptors (DR4 and DR5) and their cognate ligands (e.g. TRAIL). 29, 30 We have shown that combining HDACi with agonistic anti-TRAIL receptor antibodies is effective in preclinical models of breast, colon and renal carcinoma. 17, 30 In vitro sensitivity of cells to rhTRAIL correlated with surface TRAIL receptor expression ( Figures  3a and b) , with RPMI-8226 cells showing the highest expression of DR4 and DR5 and lowest apoptotic threshold in response to TRAIL (EC 50 ¼ 27 ng/ml). For the other MM cell lines expressing low levels of DR-4/5, DR-4 expression was higher in the OPM-2 cell line and more closely correlated with rhTRAIL sensitivity (EC 50 ¼ 60 ng/ml; 48 h). Combining panobinostat with rhTRAIL synergistically induced apoptosis in RPMI-8226 and U266 cells. This combination induced Calcusyn was used to determine synergy when the two agents were combined: synergy is determined when CIo0.9, additively when CI is between 0.9 and 1.1 and antagonism when CI41.1. CI values are shown on each graph combination of both agents, respectively (data not shown). Specifically, panobinostat reproducibly lowered the transcription of IL-6, IL-6R and IL-6 signal transducer in both cell types, whereas 5-AZA reduced IL-6 transcription in U266 cells only. Combination treatment further reduced IL-6 in U266 cells only. Taken together, the reduced expression of IL-6 was not a common effect of combination therapy and unlikely to facilitate drug synergy in both cell lines. Gene set enrichment analysis utilizing CAMERA (correlation adjusted mean rank) 40 revealed distinct molecular signatures when JJN3 and U266 cells were treated with combination therapies not seen during single-agent dosing (Figures 4c and d) (Tables 1a and b). We purport that the greater number of unique gene sets affected by combination therapy in JJN3 cells, which include relevant HDACi, methylation and MM signaling pathways may reflect the greater induction of apoptosis in this MM cell line than U266. In addition, we observed upregulation of a single gene set signature common to both cell lines that was unique to the combination therapy ( Figure 4e and Table 1c ). This suggests that activation of cell-line-specific molecular signatures may enable amplification of the synergistic apoptotic response when panobinostat and 5-AZA were combined. (Figures 6a and  b) . In contrast, single-agent ABT-737 had neither effect on serum paraprotein nor the survival of mice bearing Vk*MYC MM (median ¼ 11 days). Unfortunately, although serum paraprotein was significantly reduced (data not shown), the combination of panobinostat with ABT-737 led to all mice reaching end points by day 3 of treatment, putatively because of drug-induced toxicity (Figures 6a and b) . Mice bearing Vk*MYC tumors were then treated with vehicle, low-dose panobinostat (5 mg/kg), ABT-737 (50 mg/kg) or the combination. The dose of panobinostat used was the maximumtolerated dose when combined with ABT-737 (data not shown). Panobinostat significantly reduced paraprotein levels compared with vehicle-treated control levels (day 26, Po0.05), whereas ABT-737 had no significant effect (P40.05) over the period of therapy (Figure 6c ). Therefore, in contrast to in vitro data, combining both agents had no additional effect on serum paraprotein levels achieved by panobinostat treatment alone (P40.05) and no survival advantage was observed using the combination regimen (Figure 6d ).
Mice bearing Vk*MYC tumor were treated with vehicle, panobinostat, MD5-1 and the combination. A significant reduction in serum paraprotein was observed after 5 days of panobinostat treatment, and further reduced in mice receiving combination treatment compared with vehicle controls (Figures 7a, Po0.05) . No change to serum paraprotein levels were observed with mice receiving MD5-1 treatment at this time (P40.05). Survival of mice receiving panobinostat alone was significantly increased compared with vehicle-treated mice (median ¼ 40 versus 26.5 days, Po0.05) (Figure 7b ). In contrast, MD5-1-treated mice showed no survival benefit over mice treated with vehicle (median ¼ 24 versus 26.5 days; P40.05), whereas all mice receiving combination therapy reached end points by day 10. These early deaths occurred in the combination treatment group despite significant reductions in tumor burden as assessed by reduction in serum paraprotein, indicating mortality due to drug toxicity Figure 4b ) and assessed for changes in gene expression using next-generation RNA sequencing after 24 h. Gene set enrichment was assessed using CAMERA. 40 Each Venn diagram depicts the number of MSigDB gene sets enriched within each treatment and within each cell line (two-sided Po0.05, n ¼ 3); (e) demonstrates the number of distinct or overlapping MSigDB gene sets enriched when JJN3 or U266 cells were treated with the combination of panobinostat with 5-AZA rather than disease progression. In an attempt to overcome the toxicities observed, the dose of panobinostat was reduced. Treatment with panobinostat alone (7.5 mg/kg) led to significant reductions in serum paraprotein (Po0.05), whereas MD5-1 alone, and its combination with panobinostat, had no significant effect (P40.05) (Figure 7c ). Treatment with panobinostat resulted in an increase in survival of tumorbearing mice compared with vehicle treatment (median ¼ 18 versus 39 days, Po0.05), whereas MD5-1 had a marginal effect on mouse survival (median ¼ 18 versus 25 days, P40.05) (Figure 7d ). Interestingly, even with the reduced dosage of panobinostat, combination treatment with MD5-1 was still intolerable with mice succumbing earlier than vehicletreated mice (median ¼ 18 versus 15 days, P40.05) (Figure 7d ). Similar toxicities using the combination of panobinostat and MD5-1 were observed in mice bearing a second independently derived Vk*MYC myeloma (data not shown).
To determine whether the toxicity of combined panobinostat/MD5-1 treatment was due to direct effects on host cells, the experiment was repeated using C57BL/6.DR5 À / À mice bearing transplanted Vk*MYC tumor. Mice were treated with vehicle, panobinostat (7.5 mg/kg), MD5-1 (50 mg per mouse) and the combination of both agents. In contrast to experiments in wild-type mice, no dose-limiting toxicity was observed ( Figure 7e ). As shown previously, MD5-1 treatment alone had no effect on survival compared with control-treated mice (median ¼ 27.5 versus 30.5 days, P40.05), whereas panobinostat alone significantly increased the median survival time (median ¼ 39.5 days, Po0.05). Remarkably, in the absence of on-target toxicity, the combination of panobinostat and MD5-1 provided the greatest survival advantage in tumor-bearing C57BL/6.DR5
À / À mice with a significant increase in survival compared with vehicle-treated mice (median ¼ 54 versus 30.5 days; Po0.05) (Figure 7e) .
Finally, mice bearing Vk*MYC tumor were treated with vehicle, panobinostat, 5-AZA or the combination. After 12 days of treatment, a significant reduction in serum paraprotein was observed in panobinostat-and 5-AZA-treated mice that were further reduced when the two agents were combined (Figure 7f) . Importantly, the combination of panobinostat with 5-AZA led to the greatest survival advantage in tumor-bearing mice over vehicle-treated mice, greater than doubling their survival time (median ¼ 32 versus 68.5 days; Po0.05) (Figure 7g ).
Discussion
MM is an incurable malignancy with an unmet need for novel therapeutic agents. 5 Here, we combined in vitro cell linebased profiling with in vivo pre-clinical screening utilizing syngeneic transplanted Vk*MYC MM to investigate efficacy and safety of single-agent and combination therapies. HDACi were the primary agents under investigation and these were combined with ABT-737 targeting the intrinsic apoptosis pathway; rhTRAIL/MD5-1 that activates the extrinsic pathway or the DNMTi 5-AZA. We demonstrate that while in vitro studies provide some insight into drug combinations that synergistically kill MM cells, they do not guarantee their efficacy or tolerability in vivo. Our results provide evidence that Vk*MYC MM may aid in predicting clinical utilization of novel therapies by eliminating ineffective drug combinations and identifying associated on-target toxicities. Moreover, we describe the potential for HDACi to synergize with agents inhibiting DNA methylation, such as 5-AZA, in MM.
Recent investigations have highlighted the potential for HDACi in the treatment of MM. 41, 42 Indeed, the Vk*MYC model has proven useful in predicting that the combination of HDACi with bortezomib would be safe and effective for the treatment of MM. 35 Here, we demonstrated the induction of apoptosis in four human MM cell lines by vorinostat, panobinostat and romidepsin concomitant with on-target histone H3 acetylation. Owing to the low nanomolar activity of panobinostat in vitro and current phase III testing, this panHDACi was utilized in all further single-agent and combination experiments.
Previous investigators have suggested that the expression of prosurvival Bcl-2 family proteins can determine HDACi sensitivity. 38, 43, 44 Therefore, we assessed Bcl-2, Bcl-X L , Bcl-w, Mcl-1 and A1. Bcl-2 and Bcl-X L expression levels were varied, whereas high levels of Mcl-1 remained relatively constant between cell lines (Bcl-w and A1 were not detected). This suggests that expression of Bcl-2 family proteins does not adequately predict sensitivity to panobinostat within CAMERA results for the gene sets from the MSigDB from panobinostat-and 5-AZA-treated U266 cells. Data include the size of each set, direction of gene set alterations, two-sided P-value and FDR this study. However, expression of Bcl-2 and Bcl-X L in these MM cells provided a molecular rationale for testing the ability of ABT-737 to synergize with panobinostat. Combining panobinostat with ABT-737 over a broad concentration range resulted in significant induction of apoptosis in all MM cell lines tested. The level of apoptosis induced was more than additive and most likely due to concomitant activation of the intrinsic death pathway by both agents. 16, 25 These in vitro results suggested the potential for this drug combination in treating MM.
A second therapy investigated, combining panobinostat with rhTRAIL, was based on the significant expression of death receptors DR-4 and DR-5 on two of the human MM cell lines tested. Previous investigators have documented the sensitivity of various MM cell lines to TRAIL-induced cell death, and the capability of HDACi to synergize with rhTRAIL through mechanisms including reactivation of silenced caspase-8, 12 downregulation of c-FLIP 12,27,45-47 and restoration of cell surface DR-4/5 expression. 48 We demonstrated synergistic induction of apoptosis in OPM-2 and RPMI-8226 cells when panobinostat was combined with rhTRAIL. This marked synergism was also detected in U266 cells, which express very low levels of DR-4/5 and are insensitive to single-agent rhTRAIL. Furthermore, we observed that panobinostat treatment increased surface DR-5 expression and loss of c-FLIP L in a cell line-dependent manner.
Previous studies investigating appropriate drug combinations for the treatment of MM have utilized human xenografts and immunodeficient mice. 26, 49, 50 The Vk*MYC model faithfully mimics human MM and provides a physiologically relevant tool for preclinical screening of novel therapeutics. 3, 35 Transplanted Vk*MYC MM enables testing of therapeutics in younger mice without the time and expense involved in aging de novo Vk*MYC mice. Utilizing wild-type C57BL/6 mice bearing Vk*MYC tumor cells, we demonstrated that although in vitro cell culture studies suggest that a drug combination might be effective, these in vitro studies do not always translate in vivo. As an example, while combined panobinostat and ABT-737 induced synergistic death of human MM cell lines in vitro, the combination was too toxic and provided no significant survival benefit over panobinostat alone when tested at the MTD in vivo. This is considering a large reduction in paraprotein levels detected in combination treated mice (day 3, data not shown). It is important to consider the biological consequences of interactions between MM cells and the microenvironment within the bone marrow niche that may protect against ABT-737-induced apoptosis. Indeed, ABT-737 and its analog ABT-263 show reduced efficacy against nodally based CLL cells compared with circulating disease. 51, 52 This might explain the divergent efficacy of ABT-737 against MM cell lines tested in vitro compared with Vk*MYC MM cells resident in the transplanted host.
In contrast to the effects of ABT-737, the agonistic anti-DR5 monoclonal antibody MD5-1 synergized with HDACi to kill human MM cell lines in vitro and induce myeloma regressions in vivo. However, this was achieved at the expense of prohibitive on-target in vivo toxicity conferred by the combination regimen. Importantly, the efficacy of combined panobinostat and MD5-1 could be maintained in the absence of toxicity in DR-5 knockout recipient mice in agreement with our previous studies. 17 Therefore, combined rhTRAIL/HDACibased strategies may be used to overcome MM drug resistance in the human setting, if dose-limiting toxicities can be managed.
Profiling drug combinations using in vitro cell line-based investigations and Vk*MYC MM highlighted synergy when panobinostat is combined with 5-AZA. RNA sequencing of human MM cell lines JJN3 and U266 highlight distinct molecular signatures that may explain the potent cell line-dependent synergies seen when the two agents are combined. Importantly, our results suggest that targeting the epigenome through two molecularly distinct mechanisms, by coadministration of HDACi and DNMTi, has the ability to enhance the sensitivity of MM cells to apoptosis induction, leading to greater survival in mice bearing Vk*MYC MM.
These comprehensive studies into combination therapies consisting of panobinostat with ABT-737, rhTRAIL/MD5-1 or 5-AZA demonstrate the potential for Vk*MYC MM as a preclinical screening tool. In line with our recent publication, 35 we clearly demonstrate that panobinostat treatment provides a significant survival advantage with even relatively low dosages of drug. Importantly, the use of Vk*MYC MM allowed us to document the lack of activity of ABT-737 when combined with panobinostat and identify a toxicity profile observed following combination of panobinostat with MD5-1 that restricts efficacious dosing of this dual treatment regimen. Remarkably, we report the synergistic induction of apoptosis in vitro when panobinostat is combined with 5-AZA that is demonstrated by significant reductions to tumor load in vivo and increased survival advantage. These studies provide evidence that Vk*MYC MM is a useful screening tool for anti-MM drugs and should aid in prioritization of novel drug testing in the clinic. In vitro apoptosis. Cells seeded (2-5 Â 10 5 per well) into 24-well plates (750 ml) were treated with vorinostat, panobinostat, romidesin, ABT-737, rhTRAIL or 5-AZA (750 ml). For combination studies, MM cell lines were treated with panobinostat and ABT-737, rhTRAIL or 5-AZA in a checkerboard format: vehicle (750 ml medium); single agent for each drug (375 ml drug þ 375 ml medium); and combination drug treatments (375 ml drug A þ 375 ml drug B). 53 Samples (20-40 mg) run into an SDS-PAGE gel (8-12%), wet transferred onto Immobilin P membrane (Millipore) and blocked (1 h, 5% skim milk). Primary antibodies were prepared in 5% skim milk in Tris-buffered saline with Tween (TBS-T) as follows: anti-acetylated histone H3, anti-Bcl-2, anti-Bcl-X L , anti-Bcl-w, anti-Bcl-A1, anti-Mcl-1 and anti-cFLIP at 1/1000. b-Actin or a-tubulin (1/2000) were used as loading controls. Primary antibodies were incubated overnight at 4 1C. Secondary antibodies were prepared in 5% skim milk in TBS-T and incubated for 1 h at room temperature. Membranes were exposed to film after the addition of ECL (GE Healthcare, Melbourne, VIC, Australia). For assessment of c-FLIP mRNA expression, total RNA was obtained from cell pellets using Qiagen RNeasy mini kits (Qiagen, Doncaster, VIC, Australia) and reverse transcribed using M-MLV Reverse transcriptase (RNase H Minus, Point mutant) and random primers (Promega, Madison, WI, USA). Quantitative real-time polymerase chain reaction was undertaken using SYBR green fluorescent nucleic acid stain (Invitrogen, Mulgrave, VIC, Australia) and the following primers (Fwd: RNA sequencing. JJN3 and U266 cells were treated with panobinostat (4 h), 5-AZA (24 þ 4 h) or the combination of both agents (24 þ 4 h) at doses deemed to be synergistic (Figure 4b ), harvested and RNA extracted as described. Fifty base pair paired-end reads were generated on an Illumina Hiseq. Reads were quality checked by FastQC and trimmed if necessary for low base quality or adaptor, and then mapped to the human reference genome (GRCh37) using Tophat2 v.2.0.8b (PMID: 23618408) with maximum number of multiple hits set to 1 and using the option to map first to the reference ; panobinostat (7.5 mg/kg, n ¼ 7); MD5-1 (50 mg per mouse; days 2, 5, 9, 12; n ¼ 6); or the combination of both agents (n ¼ 7); (d) survival of mice treated as per (c); (e) absence of on-target MD5-1-mediated toxicity by treatment of C57BL/6.DR5 KO mice bearing Vk*MYC tumor with panobinostat and MD5-1 combination therapy leads to significant increases in survival. Mice were treated as follows: vehicle (D5W±control antibody UC81B9, n ¼ 6); panobinostat (7.5 mg/kg, n ¼ 6); MD5-1 (50mg per mouse, days 2, 5, 9, 12; n ¼ 6); or the combination of both agents (n ¼ 7); (f) normalized M-spike of mice bearing Vk*MYC MM treated as follows: vehicle (D5W, n ¼ 6), panobinostat (10 mg/kg, n ¼ 6), 5-AZA (5 mg/kg, n ¼ 7) and the combination of both agents (n ¼ 7). (g) Survival of mice treated as per (f). *Po0.05 versus vehicle and # Po0.05 versus initial (pretreatment) SPEP transcriptome (Ensembl v.69). Counts per gene were obtained using HTSeq v.0.5.3p9 with mode intersection-nonempty (http: //www-huber.embl.de/users/ anders/HTSeq/doc/overview.html/). The limma-voom method was used to identify genes differentially expressed between each drug (or combination) and the vehicle control using a FDR threshold o0.05 (http: //www.statsci.org/ smyth/pubs/VoomTechReport.pdf/).
Gene set testing was performed using CAMERA 40 and the MSigDB v.3.1 C2 curated gene sets collection. The genes in the RNA-seq data set were mapped to the Entrez IDs in the gene sets by first mapping the RNA-seq Ensembl gene IDs to Entrez IDs. Gene sets that contained fewer than 15 genes were excluded. After running CAMERA, two-sided P-values of o0.05 were applied to identify statistically significant signatures. Therapeutic assessment of antitumor agents. Recipient C57BL/6 mice (typically n ¼ 10 per intended treatment cohort) were injected intravenously with Vk*MYC MM cells (2-5 Â 10 5 per mouse) following conditioning with two fractions of 3 Gy irradiation. Mice were monitored for the onset of paraproteinemia by periodic serum protein electrophoresis (SPEP). Mice with established paraproteinemia (45% of total protein) were grouped based on approximately equal mean paraprotein levels and randomly assigned to treatment groups. For determination of 'on-target' toxicity in response to MD5-1 treatment, Vk*MYC tumor was transplanted into C57BL/6.DR5 À / À mice. Mice bearing Vk*MYC tumor were treated for 4 weeks as follows: (a) vehicle (D5W, 200 ml daily), panobinostat (25 mg/kg days 1-4, then 15 mg/kg 5 days per week); (b) panobinostat (10, 7.5 or 5 mg/kg, 5 days per week, intraperitoneally), ABT-737 (75 or 50 mg/kg, intraperitoneally, two times daily), or the combination of both agents; (c) monoclonal control antibody (UC8-1B9, 50 mg per mouse) in D5W, panobinostat (10 g or 7.5 mg/kg), anti-mouse agonistic anti-TRAIL antibody MD5-1 (50 mg per mouse or 25 mg per mouse) or the combination of both agents; and (d) panobinostat (10 mg/kg 5days per week, intraperitoneally), 5-AZA (5 mg/kg, two times daily, 12 days, intraperitoneally) or the combination of both agents. Therapeutic efficacy was assessed by serial SPEP obtained by retro-orbital sampling or tail grazing. Mice were culled by cervical dislocation at predetermined end points, including hind limb paralysis, cachexia and hunching.
Analysis of DR
Mice were maintained under specific pathogen-free conditions and used in accordance with the institutional guidelines of the Peter MacCallum Cancer Centre. Animal care was provided in accordance with the procedures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
